Visual Abstract: Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology, Clinical Outcomes

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, SEPTEMBER 12, 2022

Media advisory: The full study is linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2022.2793?guestAccessKey=4d5bb88d-c490-457c-920e-3aa86ab39f37&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091222

 

Visual Abstract

Authors: John R. Sims, M.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.

(doi:10.1001/jamaneurol.2022.2793)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.